论文部分内容阅读
作者采用分枝杆菌疫苗(SRL172)与标准抗痨化疗联合治疗HIV阳性肺结核患者,旨在通过以下机制加强抗痨治疗的效果和降低死亡率:恢复宿主对分枝杆菌抗原的识别和促进Th1对抗原的应答;减少CD8~+细胞毒性T淋巴细胞;下调能产生IL-4和IL-5的T细胞比例,以达到阻断免疫病理机制对组织的损伤和增加胞内杀菌的效果,提高治愈率。
The authors used mycobacterial vaccine (SRL172) in combination with standard anti-tuberculosis chemotherapy in the treatment of HIV-positive tuberculosis patients to enhance anti-tuberculosis treatment and reduce mortality through the following mechanisms: To restore the host’s recognition of mycobacterial antigens and to promote Th1 Antigen response; Reduce CD8 ~ + cytotoxic T lymphocytes; Down regulate the proportion of T cells that can produce IL-4 and IL-5 in order to block the immune pathological mechanism of tissue damage and increase the effect of intracellular bactericidal and improve the cure rate.